Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Sara A. Hurvitz presents the primary results from the DESTINY-Breast12 trial, highlighting the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive advanced/metastatic breast cancer, including those with stable or active brain metastases​.

Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary Results